Annual Drug Patent Expiration for HETLIOZ
Hetlioz is a drug marketed by Vanda Pharms Inc and included in two NDAs. It is available from a single supplier. There are twenty-one patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for HETLIOZ.
This drug has one hundred and ninety-two patent family members in thirty-one countries.
The generic ingredient in HETLIOZ is tacimelteon. One registered supplier for this compound. Additional details are available on the tasmelteon profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published in New patent for the Vanda Pharms drug HETLIOZ